12 research outputs found
Supplementary Figure S6 from Neoantigen Targetability in Progressive Advanced Melanoma
Expression of tumor associated antigens in early and later metastatic lesions.</p
Supplementary Figure S3 from Neoantigen Targetability in Progressive Advanced Melanoma
T cell recognition of melanoma cell lines derived from early and later metastatic lesions.</p
Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
Eluted tumor-associated antigen-derived peptides.</p
Supplementary Figure S5 from Neoantigen Targetability in Progressive Advanced Melanoma
Putative neoantigens in early and later metastatic lesions.</p
Supplementary Figure S1 from Neoantigen Targetability in Progressive Advanced Melanoma
Immunohistochemical staining of proteins involved in T cell recognition and/or inhibition.</p
Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
Tumor characteristics.</p
Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
HLA class I genotypes as determined by exome and transcriptome sequencing.</p
Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
Tumor-associated antigen peptide sequences assessed for elution.</p
Supplementary Methods S1 from Neoantigen Targetability in Progressive Advanced Melanoma
More detailed information on: 1) Immune-fluorescent staining, 2) Mass spectrometry, 3) MLTC and TIL cultures.</p
Supplementary Figure S4 from Neoantigen Targetability in Progressive Advanced Melanoma
HLA class II expression and recognition of early and later metastatic lesion- derived tumor cells
from patient Mel5 by CD4+ and CD8⁺ T cells.</p